Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-year profit forecast due to weaker demand and increased price sensitivity among pet owners. Investors who purchased Zoetis securities during the class period have until July 27, 2026, to join the lawsuit or seek lead plaintiff status. This legal action follows a 21.5% stock price decline after the earnings announcement, highlighting investor concerns about Zoetis' future performance.
Zoetis reported mixed earnings for Q2 and lowered its future guidance, reflecting challenges in U.S. pet-related sales. However, strong performance in other business segments helps balance the impact. Despite near-term difficulties, the overall risk/...
Zoetis (ZTS), a global leader in animal health products, now trades at a forward price-to-earnings ratio of 12 and offers a nearly 3% dividend yield after a prolonged price decline. Despite facing competition, weaker U.S. companion animal sales, and ...
